

Atty. Docket No. 7660XC
Preliminary Amdt. dated October , 2003
Customer No. 27752

AMENDMENTS TO THE SPECIFICATION

Please amend the specification as follows:

Please insert the following paragraph before the FIELD OF THE INVENTION paragraph:

This application is a continuation under 37 CFR §1.53(d) of US application serial no. 09/980,799, filed December 3, 2001, which claims priority under 35 USC §119(e) to US Provisional appln. No(s). 60/160,431, filed October 19, 1999, 60/160,324, filed October 19, 1999, 60/160,272, filed October 19, 1999, 60/160,289, filed October 19, 1999, 60/144,321, filed July 16, 1999, 60/144,110, filed July 16, 1999, 60/144,113, filed July 16, 1999, and 60/144,111, filed July 16, 1999.

Please replace the paragraph beginning at page 38, line 29 – page 39, line 5, with the following rewritten paragraph:

Preferred bleach activators are those described in U.S. 5,698,504 Christie et al., issued December 16, 1997; U.S. 5,695,679 Christie et al. issued December 9, 1997; U.S. 5,686,401 Willey et al., issued November 11, 1997; U.S. 5,686,014 Hartshorn et al., issued November 11, 1997; U.S. 5,405,412 Willey et al., issued April 11, 1995; U.S. 5,405,413 Willey et al., issued April 11, 1995; U.S. 5,130,045 Mitchel et al., issued July 14, 1992; and U.S. 4,412,934 Chung et al., issued November 1, 1983, and ~~expending patent applications U. S. Serial Nos. 08/709,072, 08/064,564 WO 94/28104~~; acyl lactam activators, as described in U.S. 5,698,504, U.S. 5,695,679 and U.S. 5,686,014, each of which is cited herein above, are very useful herein, especially the acyl caprolactams (see for example WO 94-28102 A) and acyl valerolactams, U.S. 5,503,639 Willey et al., issued April 2, 1996 all of which are incorporated herein by reference.

Please replace the paragraph beginning at page 47, lines 1-12, with the following rewritten paragraph:

amino acid residue position corresponding to position 103 of *Bacillus amyloliquefaciens* subtilisin in combination with a substitution of an amino acid residue with another naturally occurring amino acid residue at one or more amino acid residue positions corresponding to positions 1, 3, 4, 8, 9, 10, 12, 13, 16, 17, 18, 19, 20, 21, 22, 24, 27, 33, 37, 38, 42, 43, 48, 55, 57, 58, 61, 62, 68, 72, 75, 76, 77, 78, 79, 86, 87, 89, 97, 98, 99, 101, 102, 104, 106, 107, 109, 111, 114, 116, 117, 119, 121, 123, 126, 128, 130, 131, 133, 134, 137, 140, 141, 142, 146, 147, 158, 159, 160, 166, 167,

Atty. Docket No. 7660XC
 Preliminary Amdt. dated October , 2003
 Customer No. 27752

170, 173, 174, 177, 181, 182, 183, 184, 185, 188, 192, 194, 198, 203, 204, 205, 206, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 222, 224, 227, 228, 230, 232, 236, 237, 238, 240, 242, 243, 244, 245, 246, 247, 248, 249, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 265, 268, 269, 270, 271, 272, 274 and 275 of *Bacillus amyloliquefaciens* subtilisin; wherein when said protease variant includes a substitution of amino acid residues at positions corresponding to positions 103 and 76, there is also a substitution of an amino acid residue at one or more amino acid residue positions other than amino acid residue positions corresponding to positions 27, 99, 101, 104, 107, 109, 123, 128, 166, 204, 206, 210, 216, 217, 218, 222, 260, 265 or 274 of *Bacillus amyloliquefaciens* subtilisin and/or multiply-substituted protease variants comprising a substitution of an amino acid residue with another naturally occurring amino acid residue at one or more amino acid residue positions corresponding to positions 62, 212, 230, 232, 252 and 257 of *Bacillus amyloliquefaciens* subtilisin as described in ~~PCT Application Nos. PCT/US98/22588, PCT/US98/22482 and PCT/US98/22486 all filed on October 23, 1998 from The Procter & Gamble Company (P&G Cases 7280&, 7281& and 72821, respectively)~~ WO 99/20727, WO 99/20726, and WO 99/20723.

Please replace the paragraph beginning at page 52, line 30 – page 53, line 7, with the following rewritten paragraph:

The alkaline mannanase from *Bacillus agaradherens* NCIMB 40482 is described in the co-pending U.S. patent application serial No. 09/111,256, now abandoned. More specifically, this mannanase is:

- i) a polypeptide produced by *Bacillus agaradherens*, NCIMB 40482; or
- ii) a polypeptide comprising an amino acid sequence as shown in positions 32-343 of SEQ ID NO:2 as shown in U.S. patent application serial No. 09/111,256, now abandoned; or
- iii) an analogue of the polypeptide defined in i) or ii) which is at least 70% homologous with said polypeptide, or is derived from said polypeptide by substitution, deletion or addition of one or several amino acids, or is immunologically reactive with a polyclonal antibody raised against said polypeptide in purified form.

Please replace the paragraph beginning at page 53, lines 8 - 20, with the following rewritten paragraph:

Atty. Docket No. 7660XC
Preliminary Amdt. dated October , 2003
Customer No. 27752

Also encompassed is the corresponding isolated polypeptide having mannanase activity selected from the group consisting of:

- a) polynucleotide molecules encoding a polypeptide having mannanase activity and comprising a sequence of nucleotides as shown in SEQ ID NO: 1 from nucleotide 97 to nucleotide 1029 as shown in U.S. patent application serial No. 09/111,256, now abandoned;
- b) species homologs of (a);
- c) polynucleotide molecules that encode a polypeptide having mannanase activity that is at least 70% identical to the amino acid sequence of SEQ ID NO: 2 from amino acid residue 32 to amino acid residue 343 as shown in U.S. patent application serial No. 09/111,256, now abandoned;
- d) molecules complementary to (a), (b) or (c); and
- e) degenerate nucleotide sequences of (a), (b), (c) or (d).

Please replace the paragraph beginning at page 53, line 21 – page 54, line 6, with the following rewritten paragraph:

A second more preferred enzyme is the mannanase from the *Bacillus subtilis* strain 168, which is described in the ~~co-pending U.S. patent application serial No. 09/095,163~~ WO 99/64573. More specifically, this mannanase is:

- i) is encoded by the coding part of the DNA sequence shown in SED ID No. 5 shown in the ~~U.S. patent application serial No. 09/095,163~~ WO 99/64573 or an analogue of said sequence; and/or
- ii) a polypeptide comprising an amino acid sequence as shown SEQ ID NO:6 shown in the ~~U.S. patent application serial No. 09/095,163~~ WO 99/64573; or
- iii) an analogue of the polypeptide defined in ii) which is at least 70% homologous with said polypeptide, or is derived from said polypeptide by substitution, deletion or addition of one or several amino acids, or is immunologically reactive with a polyclonal antibody raised against said polypeptide in purified form.

Please replace the paragraph beginning at page 54, lines 7 - 17, with the following rewritten paragraph:

Also encompassed in the corresponding isolated polypeptide having mannanase activity selected from the group consisting of:

- a) polynucleotide molecules encoding a polypeptide having mannanase activity and comprising a sequence of nucleotides as shown in SEQ ID NO:5 as shown in the ~~U.S. patent application serial No. 09/095,163~~ WO 99/64573;
- b) species homologs of (a);

Atty. Docket No. 7660XC
Preliminary Amdt. dated October , 2003
Customer No. 27752

- c) polynucleotide molecules that encode a polypeptide having mannanase activity that is at least 70% identical to the amino acid sequence of SEQ ID NO: 6 as shown in the U.S. patent application serial No. 09/095,163 WO 99/64573;
- d) molecules complementary to (a), (b) or (c); and
- e) degenerate nucleotide sequences of (a), (b), (c) or (d).

Please replace the paragraph beginning at page 71, lines 7 - 8, with the following rewritten paragraph:

8. Protease variants at position 103 of *Bacillus amyloliquefaciens* as described in PCT/US98/22588 (Publishes 29 Apr 99) WO 99/20727.

Please replace the paragraph beginning at page 72, lines 10 - 11, with the following rewritten paragraph:

7. Protease variants at position 103 of *Bacillus amyloliquefaciens* as described in PCT/US98/22588 (Publishes 29 Apr 99) WO 99/20727.

Please replace the paragraph beginning at page 73, lines 18 - 19, with the following rewritten paragraph:

8. Protease variants at position 103 of *Bacillus amyloliquefaciens* as described in PCT/US98/22588 (Publishes 29 Apr 99) WO 99/20727.

Please replace the paragraph beginning at page 74, lines 25 - 26, with the following rewritten paragraph:

8. Protease variants at position 103 of *Bacillus amyloliquefaciens* as described in PCT/US98/22588 (Publishes 29 Apr 99) WO 99/20727.

Please see a replacement (or new) abstract on the attached separate sheet.